# NephroGenex

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nephrogenex

- Industry: Pharmaceuticals
- Headquarters: US
- Website: www.nephrogenex.com
- Total disclosed funding: $29M
- Latest round: Series A (Jun 11, 2008)
- Investors on record: 4

## About

NephroGenex, Inc. is a biotechnology company dedicated to developing innovative therapies for treating kidney diseases, particularly diabetic nephropathy, with a focus on improving patient outcomes through advanced clinical research.NephroGenex, Inc. specializes in therapies for kidney diseases and is headquartered in the US. The company went public in February 2014, raising USD 37 mn by issuing 3.1 million shares at an exit share price of USD 12. Wesley Fox serves as the CEO.NephroGenex, Inc. primarily focuses on the development and commercialization of innovative therapies aimed at treating kidney diseases, with a particular emphasis on diabetic nephropathy. Their lead product, PYRIDORIN® (pyridoxamine dihydrochloride), functions as a scavenger of oxidative chemistries that contribute to the pathogenesis of diabetic nephropathy and end-stage renal disease. By targeting these harmful chemistries, PYRIDORIN® aims to slow disease progression, as evidenced by positive outcomes in Phase 2 clinical studies. The company is currently enrolling participants in the pivotal Phase 3 PIONEER study to further evaluate the drug's efficacy. NephroGenex's products are primarily directed toward healthcare providers and institutions involved in nephrology, particularly within the United States, where there is significant unmet medical need in the treatment of diabetic nephropathy.NephroGenex generates revenue through the development and potential commercialization of its lead product, PYRIDORIN®. The company's revenue model is structured around partnerships with pharmaceutical distributors and healthcare providers, facilitating the delivery of their therapies to end-users in clinical settings. As the company progresses through its clinical trials, successful outcomes may lead to pricing arrangements and licensing agreements with larger pharmaceutical entities. In the most recent fiscal year, NephroGenex reported an EBITDA of USD -22.31 mn, reflecting the ongoing investment in clinical development.Looking ahead, NephroGenex plans to leverage its recent funding to advance the development of PYRIDORIN® and expand its market presence. Following the successful completion of the Phase 3 PIONEER study, the company aims to seek regulatory approvals for its lead product and explore potential international markets. The recent PIPE funding round raised USD 5.5 mn, which will support these initiatives and enhance strategic partnerships with healthcare institutions. NephroGenex is poised to venture into new territories following positive clinical trial results.

## Funding rounds

- Series A, Jun 11, 2008, $25M — Care Capital, BioStratum, Inc.
- Series A, May 14, 2007, $3.1M — Care Capital, Vanderbilt University Endowment, BioStratum, Inc.
- Seed, Nov 8, 2004, $0.5M — Vanderbilt University Endowment, Karolinska Development

## Investors

- Vanderbilt University Endowment — Seed, Series A
- Karolinska Development — Seed
- Care Capital (https://capitalatlas.ai/funds/care-capital) — Series A
- BioStratum, Inc. — Series A